1. Home
  2. ADPT vs AORT Comparison

ADPT vs AORT Comparison

Compare ADPT & AORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • AORT
  • Stock Information
  • Founded
  • ADPT 2009
  • AORT 1984
  • Country
  • ADPT United States
  • AORT United States
  • Employees
  • ADPT N/A
  • AORT N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • AORT Medical/Dental Instruments
  • Sector
  • ADPT Health Care
  • AORT Health Care
  • Exchange
  • ADPT Nasdaq
  • AORT Nasdaq
  • Market Cap
  • ADPT 1.8B
  • AORT 1.9B
  • IPO Year
  • ADPT 2019
  • AORT 1993
  • Fundamental
  • Price
  • ADPT $12.92
  • AORT $43.02
  • Analyst Decision
  • ADPT Strong Buy
  • AORT Strong Buy
  • Analyst Count
  • ADPT 8
  • AORT 6
  • Target Price
  • ADPT $12.38
  • AORT $39.80
  • AVG Volume (30 Days)
  • ADPT 2.1M
  • AORT 521.6K
  • Earning Date
  • ADPT 08-05-2025
  • AORT 08-07-2025
  • Dividend Yield
  • ADPT N/A
  • AORT N/A
  • EPS Growth
  • ADPT N/A
  • AORT N/A
  • EPS
  • ADPT N/A
  • AORT N/A
  • Revenue
  • ADPT $205,216,000.00
  • AORT $405,037,000.00
  • Revenue This Year
  • ADPT $24.39
  • AORT $12.20
  • Revenue Next Year
  • ADPT $20.44
  • AORT $10.63
  • P/E Ratio
  • ADPT N/A
  • AORT N/A
  • Revenue Growth
  • ADPT 21.60
  • AORT 7.44
  • 52 Week Low
  • ADPT $3.98
  • AORT $21.97
  • 52 Week High
  • ADPT $13.37
  • AORT $43.97
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 69.79
  • AORT 83.50
  • Support Level
  • ADPT $10.66
  • AORT $30.27
  • Resistance Level
  • ADPT $13.37
  • AORT $43.97
  • Average True Range (ATR)
  • ADPT 0.81
  • AORT 1.31
  • MACD
  • ADPT 0.23
  • AORT 1.32
  • Stochastic Oscillator
  • ADPT 86.82
  • AORT 92.55

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About AORT Artivion Inc.

Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.

Share on Social Networks: